Andrew Galazka
Director/Board Member bij MedXCell SA
Profiel
Andrew Galazka is currently a Director at MedXCell SA. Previously, he held positions as a Non-Executive Director at Addex Therapeutics Ltd.
from 2010 to 2012, Director of Clinical Research at GlaxoSmithKline AG and Biogen International GmbH, and Senior Vice President and Head of New Therapeutic Areas at Serono SA in 2007.
He was also Senior Vice President and Head of Medical Affairs at Merck Serono SA. Dr. Galazka received a doctorate degree from the University of Cambridge in 1978.
Actieve functies van Andrew Galazka
Bedrijven | Functie | Begin |
---|---|---|
MedXCell SA
MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | Director/Board Member | - |
Eerdere bekende functies van Andrew Galazka
Bedrijven | Functie | Einde |
---|---|---|
ADDEX THERAPEUTICS LTD | Director/Board Member | 09-05-2012 |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Corporate Officer/Principal | 17-01-2007 |
GlaxoSmithKline AG
GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Corporate Officer/Principal | - |
Biogen International GmbH
Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. | Corporate Officer/Principal | - |
Merck Serono SA
Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Corporate Officer/Principal | - |
Opleiding van Andrew Galazka
University of Cambridge | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ADDEX THERAPEUTICS LTD | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Health Technology |
Merck Serono SA
Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Health Technology |
GlaxoSmithKline AG
GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Health Technology |
Biogen International GmbH
Biogen International GmbH Pharmaceuticals: MajorHealth Technology Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland. | Health Technology |
MedXCell SA
MedXCell SA BiotechnologyHealth Technology MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then. | Health Technology |